Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Myelodysplastic Syndromes
•
Hematology
How do you approach a patient with CMML requiring platelet transfusions?
Would you consider use of TPO-R agonists such as eltrombopag or romiplostim for a patient like this?
Related Questions
How do you sequence luspatercept and imetelstat for treatment of anemia in MDS?
How do you modify HMA treatments for a patient with high-risk MDS experiencing prolonged cytopenias after each cycle?
How do you manage high-risk MDS IB2 patients on HMA and venetoclax who develop an acute stroke requiring antiplatelet therapy?
Would you hold off iron chelation in a transfusion dependent MDS patient with elevated ferritin but with negative iron stain on the bone marrow?
How do you approach imetelstat therapy in MDS patients with baseline neutropenia or thrombocytopenia?
How do you treat patients with T-cell ALL/T-cell lymphoblastic lymphoma who have pre-existing CKD with a CrCl of 30 mL/min or less?
What is your re-immunization strategy after auto SCT for patients with myeloma on dara/len maintenance?
In light of data from TRIANGLE, ECHO, and ENRICH, what is the best strategy to treat newly diagnosed patients with the blastoid variant MCL?
Would you give GO and/or a FLT3 inhibitor for patients with AML with t(8;21) and FLT3-ITD low in addition to 7+3?
Does the presence of paraneoplastic pemphigus influence your treatment options in CLL?